Eli Lilly and Company
LLY
$896.53
$33.673.90%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.38% | 105.14% | -37.43% | 354.48% | -67.30% |
| Total Depreciation and Amortization | -1.78% | 3.39% | -4.54% | 3.86% | 12.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 299.59% | -143.66% | 1,022.77% | -108.57% | 542.67% |
| Change in Net Operating Assets | 153.39% | 32.74% | -51.21% | -22,603.06% | 99.30% |
| Cash from Operations | 186.24% | 85.33% | -32.67% | -33.35% | 153.16% |
| Capital Expenditure | -23.02% | -12.43% | -0.90% | -10.76% | -10.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -150.73% | 92.52% | -334.11% | 84.01% | -10,029.77% |
| Cash from Investing | -62.55% | 45.26% | -74.55% | 52.04% | -82.14% |
| Total Debt Issued | -- | -100.00% | -- | -100.00% | -- |
| Total Debt Repaid | -596.14% | 144.61% | -160.77% | 198.48% | -212.92% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -2.30% | 42.32% | 41.57% | -360.41% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.13% | -0.05% | -15.24% | 0.19% | 0.16% |
| Other Financing Activities | 0.66% | 95.57% | -1,408.35% | 3.81% | -491.25% |
| Cash from Financing | 142.65% | -190.23% | 712.11% | -206.67% | -86.42% |
| Foreign Exchange rate Adjustments | -88.49% | 108.87% | 130.78% | -288.85% | 480.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,170.35% | 261.39% | -74.06% | -169.19% | -80.95% |